PMID- 31207010
OWN - NLM
STAT- MEDLINE
DCOM- 20200908
LR  - 20221005
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 21
IP  - 10
DP  - 2019 Oct
TI  - Impact of intentional weight loss on diabetic kidney disease.
PG  - 2338-2341
LID - 10.1111/dom.13813 [doi]
AB  - Type 2 diabetes mellitus (T2DM) and obesity constitute interwoven pandemics 
      challenging healthcare systems in developed countries, where diabetic kidney 
      disease (DKD) is the most common cause of end-stage renal disease. Obesity 
      accelerates renal functional decline in people with T2DM. Intentional weight loss 
      (IWL) strategies in this population hold promise as a means of arresting DKD 
      progression. In the present paper, we summarize the impact of IWL strategies 
      (stratified by lifestyle intervention, medications, and metabolic surgery) on 
      renal outcomes in obese people with DKD. We reviewed the Medline, EMBASE and 
      Cochrane databases for relevant randomized control trials and observational 
      studies published between August 1, 2018 and April 15, 2019. We found that IWL 
      improves renal outcomes in the setting of DKD and obesity. Rate of progression of 
      DKD slows with IWL, but varying outcome measures among studies makes direct 
      comparison difficult. Furthermore, established means of estimating renal function 
      are imperfect owing to loss of lean muscle mass with IWL strategies. The choice 
      of optimal IWL strategy needs to be individualized; future work should establish 
      the comparative efficacy of IWL strategies in obese people with DKD to better 
      inform such decisions.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Holland, John A
AU  - Holland JA
AUID- ORCID: 0000-0001-8663-7499
AD  - Department of Medicine, St. Vincent's University Hospital, Dublin, Ireland.
FAU - Martin, William P
AU  - Martin WP
AUID- ORCID: 0000-0001-7005-3966
AD  - UCD School of Medicine, Diabetes Complications Research Centre, Conway Institute 
      of Biomolecular and Biomedical Research, School of Medicine, University College 
      Dublin, Dublin, Ireland.
FAU - Docherty, Neil G
AU  - Docherty NG
AUID- ORCID: 0000-0002-0961-2607
AD  - UCD School of Medicine, Diabetes Complications Research Centre, Conway Institute 
      of Biomolecular and Biomedical Research, School of Medicine, University College 
      Dublin, Dublin, Ireland.
AD  - Department of Gastrosurgical Research and Education, Institute of Clinical 
      Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - le Roux, Carel W
AU  - le Roux CW
AUID- ORCID: 0000-0001-5521-5445
AD  - UCD School of Medicine, Diabetes Complications Research Centre, Conway Institute 
      of Biomolecular and Biomedical Research, School of Medicine, University College 
      Dublin, Dublin, Ireland.
AD  - Department of Gastrosurgical Research and Education, Institute of Clinical 
      Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
AD  - Division of Investigative Science, Imperial College London, London, UK.
LA  - eng
GR  - WT_/Wellcome Trust/United Kingdom
GR  - 203930/WT_/Wellcome Trust/United Kingdom
GR  - 203930/B/16/Z/WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190703
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Anti-Obesity Agents)
SB  - IM
MH  - Albuminuria
MH  - Anti-Obesity Agents/therapeutic use
MH  - Bariatric Surgery
MH  - Diabetes Mellitus, Type 2/complications/therapy
MH  - *Diabetic Nephropathies/complications/physiopathology
MH  - Humans
MH  - Life Style
MH  - *Obesity/complications/therapy
MH  - Weight Loss/*physiology
MH  - Weight Reduction Programs
PMC - PMC7612029
MID - EMS139655
OTO - NOTNLM
OT  - albuminuria
OT  - bariatric surgery
OT  - biomarkers
OT  - diabetic kidney disease
OT  - obesity
OT  - type 2 diabetes mellitus
OT  - weight loss
COIS- Conflict Of Interest The authors have no relevant affiliations or financial 
      involvement with any organization or entity with a financial interest in or 
      financial conflict with the subject matter or materials discussed in the 
      manuscript. This includes employment, consultancies, honoraria, stock ownership 
      or options, expert testimony, grants or patents received or pending, or 
      royalties.
EDAT- 2019/06/18 06:00
MHDA- 2020/09/09 06:00
PMCR- 2021/11/25
CRDT- 2019/06/18 06:00
PHST- 2019/02/19 00:00 [received]
PHST- 2019/05/30 00:00 [revised]
PHST- 2019/06/11 00:00 [accepted]
PHST- 2019/06/18 06:00 [pubmed]
PHST- 2020/09/09 06:00 [medline]
PHST- 2019/06/18 06:00 [entrez]
PHST- 2021/11/25 00:00 [pmc-release]
AID - 10.1111/dom.13813 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2019 Oct;21(10):2338-2341. doi: 10.1111/dom.13813. Epub 2019 
      Jul 3.